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Selenium status in the body and proliferative activity of
malignant cells
Sir,
Avanzini and co-workers recently reported the results of
their study on serum selenium concentrations in patients with
newly diagnosed lymphoid malignancies.1 Interestingly, as
compared to controls, selenium (Se) levels were significantly
lower in patients with non-Hodgkin’s lymphoma (in a repre-
sentative sample) in IV stage and/or in those with high grade
disease. However, literature reports of serum Se levels in
patients with lymphoid malignancy or solid tumors are discor-
dant.2-4 These discrepancies may be due to case series that are
not directly comparable among themselves or with healthy
control cohorts.
It must be borne in mind that the elevated variability of
serum Se may be due to factors other than cancer such as age,
sex, body mass, dietary habits, life style (alcohol, smoking),
intercurrent disease and medications.
When considering the various biological roles of Se (prolifer-
ation and expression of oncogenes by both normal and malig-
nant cells, carcinogen metabolism, cellular immune response,
prevention of oxidative stress, apoptosis) and when addressing
the topic of whether Se is a risk factor or a protection against
cancer,5 one must evaluate selenium levels both in serum and
in biological material that integrates selenium intake and
reflects its status over the medium and long term (4 months
for red blood cells, 12 months or longer nails and hair). These
studies are however methodologically complex, and at present
various types of investigations (prospective, environmental,
epidemiological, ecological) have failed to provide conclusive
results.
Several factors may influence Se exchanges between labile
pools, deposits and cancer tissue, and we wish to point out one
important factor which has so far received little attention but
which might influence selenium profiles, namely the prolifera-
tive activity of cancer cells. Of particular interest along this line
of thought is the finding by Avanzini and co-workers of an
inverse relationship between serum selenium and b2-
microglobulin, an important index of the turnover of neoplastic
cells.
In an ongoing study on Se levels in the serum and hair of
women with breast cancer (unpublished data), we observed
that patients recruited at an early clinical stage had lower
serum Se and higher Se hair content with respect to patients at
a more advanced stage or to healthy controls:
Stage 0-I (n=42): serum Se mean value 76.2±21.7 µg/L, hair Se
content geometric mean 416.5 µg/g
Stage II-IV (n=44): serum Se mean value 81.5±22.4 µg/L, hair
Se content geometric mean 335.2 µg/g
Controls (n=86): serum Se mean value 88.6±26.4 µg/L, hair Se
content geometric mean 370.5 µg/g
Though our data fell short of statistical significance, due in
part to the wide spread of values in the series, the findings are
suggestive in light of the kinetic properties of tumor cells.6
Indeed the relationship between Se and cellular growth
emerged from our in vitro studies that showed different Se accu-
mulation and effect according to cell density in the lymphocyte
cultures used in our experiments.7 Breast cancer shows a Gom-
pertz-type growth curve with an exponential increase in the
early proliferative phases. These events, whose underlying
mechanisms also require further investigation in terms of host-
tumor interactions, might influence different aspects of Se dis-
tribution in various body districts.
In conclusion, further experimental and epidemiological
studies are warranted to better elucidate the relationships
between Se status and carcinogenesis; however, determination
of Se levels in subjects with malignancies will only contribute
data useful for the clinician when it is performed across several
body districts (blood, depots, healthy and diseased tissue) and
interpreted in the light of the proliferative characteristics of the
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Selenium and lymphoid malignancies (Reply)
Sir,
Piccinini et al.’s hypothesis that the proliferative activity of
malignant lymphoid cells and of cancer cells in general might
influence selenium status is interesting and is partially support-
ed by prior data, including our own.1 However, due to the lim-
ited evidence available on this topic, further data are needed to
confirm that enhanced selenium uptake by neoplastic tissue
may vary according to the mitotic activity of the cancer cells.
Piccinini and colleagues also addressed a fundamental issue
in epidemiologic and clinical research on the health effects of
selenium: the methodology for exposure assessment and, in
particular, the use of biomarkers as surrogate measures of sele-
nium exposure (represented in most individuals by dietary
intake). Selenium content of serum, plasma, erythrocytes,
whole blood, hair, toenails, and urine are among the biomark-
ers most frequently used in epidemiologic and clinical studies.
Serum, plasma and urine selenium are short-term markers of
exposure, whereas the remaining indicators tend to reflect long-
term selenium intake. The limitations of these indicators as sur-
rogate measures of intake have been reviewed.2 Selenium-
dependent glutathione peroxidase activity has also been evalu-
ated as a possible biomarker of exposure, but it does not
appear to be a reliable indicator of selenium intake since the
correlation between the two parameters is not linear2 and, what
is more, glutathione peroxidase activity may be induced by oxi-
dizing agents3 (including selenium itself).4,5
In our clinical studies1,6 we evaluated selenium exposure
through determination of serum selenium content, a sensitive
short-term selenium marker,2 because we were interested in a
possible relationship between the clinical characteristics of lym-
phoid malignancies and recent changes in selenium status.
Obviously the characteristic that makes serum selenium content
of interest in clinical research, i.e. its ability to reflect short-term
selenium intake, also represents a limitation in an epidemiolog-
ic setting, particularly in retrospective studies where selenium
status is likely to be affected by the disease, at least in some
body tissues. This is why we did not consider our results to be
contradictory to the prior hypothesis of a direct association
between selenium exposure and the risk of lymphoid malignan-
cies,7 though they did not add any evidence to support this
hypothesis.
Biomarkers, however, may not adequately reflect selenium
intake due to factors such as gender, body mass, medical
treatment.8-10 Moreover, concurrent exposure to other factors
such as cadmium or methionine may modify the distribution
(and therefore the levels) of selenium in peripheral tissues.11 An
influence of cadmium on selenium metabolism might explain at
least in part why lower selenium levels have generally been
observed in smokers as opposed to non-smokers,8,9,12 in spite of
the fact that tobacco smoke represents a source of selenium
exposure.13 The limitations of biomarkers in exposure assess-
ment have suggested the usefulness of evaluating average sele-
nium exposure through estimation of usual dietary intake, but
unfortunately this methodology is also subject to limitations
due to the high variability in the selenium content of foodstuffs
in several geographical areas.12,14 The degree of correlation
between selenium intake, as estimated through food diaries or
other techniques, and biomarkers as surrogate measures of
exposure has been found to be satisfactory in some studies but
not in all.8,10
An important advantage to estimating dietary intake would
be the possibility of determining the specific chemical forms of
selenium to which the human body has been exposed before
any in vivo metabolic conversion occurs. Whichever approach
is adopted in the assessment of selenium exposure – dietary
intake or biomarkers – other factors such as exposure to heavy
metals, which can markedly influence the biological activity of
selenium, should also be considered.5
Despite the complexity of epidemiologic studies on the rela-
tionship between selenium and cancer, we agree with Piccinini
et al. on the need to investigate this issue further, especially in
the light of the results of two recent studies that have analyzed
the effect of selective long-term selenium exposure (self-admin-
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When to perform peripheral blood progenitor cell col-
lection in  hematological patients?
Sir,
we read with interest the paper by Torretta et al.1 on the expe-
rience of Pavia University regarding circulating progenitor cell
collection in cancer patients. The authors stated that, using
daily flow cytometric monitorization of CD34+ cells in the
peripheral blood (PB), collections were started when these cells
reached a value of 20 µL. However, the possibility of harvesting
even though circulating CD34+ cells were below 20 µL (between
10 and 20 µL) was always considered in relation to the particu-
lar clinical history, state of disease and therapeutic strategy
adopted for each patient.
In agreement with this latter statement, we would like to
describe our experience on this topic. As Torretta et al. reported,
we usually start leukaphereses when white cells in the PB, evalu-
ated in the morning just before collection, are greater than 1000
µL and CD34+ cells greater than 20 µL. However, when making
clinical decisions, we have to consider that some patients, due to
their clinical situation such as secondary myelodysplasia,
exhausted marrow, heavy previous chemo- or radiotherapy may
have serious problems in mobilizing CD34+ progenitor cells in
the blood.2,3 This leads to the need for a larger number of proce-
dures to obtain the optimum yield of progenitor cells for a safe
engraftment. In this setting, some authors suggest a threshold
dose of 23106/kg CD34+ cells, while others refer that less than
53106/kg, although able to restore hemopoiesis in most cases,
can be responsible for delayed engraftment or defective platelet
reconstitution and recommend collecting not less than
83106/kg CD34+ cells to ensure a rapid, complete and sustained
hematopoietic recovery.4,5 We retrospectively analyzed our data
on 54 patients suffering from hematological malignancies (21
multiple myelomas, 14 acute myeloid leukemias, 10 non-Hodgk-
in’s lymphomas, 9 Hodgkin’s disease) who received high-dose
mobilizing chemotherapy plus growth factor administration (G-
CSF and in some cases GM-CSF) at our Institution between
April 1993 and July 1996. The total number of leukaphereses
performed was 159 (mean number per patient 2.9, range 1-4).
About 9 liters of blood were processed for each patient.
The amount of CD34+ cells collected at each leukapheresis
was analyzed in relation to the number of CD34+ cells in the PB,



















Figure 1. CD34+ progenitor cell content (x 106/kg) in leuka-
phereses in relation to the PB CD34+ cell concentration (/mL).
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